Excessive Pricing by Dominant Firms: Does Customer Choice Create a Safe Harbour?
EU, French and US competition law. Excessive pricing by dominant firms raises a fundamental divide between commercial pricing freedom and exploitative-abuse control. The debate
EU Inc Governance: Could VC Investors Standardise Investment Structures Across Europe?
EU Inc governance could allow investment funds to use similar investment structures from one Member State to another. But how far would that standardisation
Excessive Pricing by Dominant Companies Across Major Jurisdictions
Excessive pricing by dominant companies is treated differently across major competition-law systems. This debate tests whether customer choice preserves pricing freedom despite abuse-of-dominance rules
Competitor information exchange: Can Future Cost Forecasts Be Shared?
EU and French competition law. Competitor information exchange can create substantial antitrust exposure when commercially sensitive data concern future business conditions. The debate tests
Below-threshold merger review: Can Competition Authorities Act After Closing?
EU and comparative competition law. Below-threshold merger review has become a material transaction-risk issue for acquirers. The debate tests the legal certainty created by
Omnibus CSRD: Can a Company Refuse ESG Data Requests?
Omnibus CSRD: can a company refuse ESG questionnaires from a bank, investor or major customer where it is no longer subject to mandatory CSRD
Dynamic IP Address: Is It Still Personal Data?
Can a dynamic IP address fall outside the scope of personal data as a result of recent European decisions?This debate tests the boundary between
Digital Cold War: Has the DMA Triggered a Transatlantic Conflict ?
Are we entering a digital Cold War as a result of the European Union’s regulation of foreign technology companies? This extreme narrative is about
Director Liability After Board Approval: Does Majority Approval Create Immunity?
Comparative corporate law ; United States, United Kingdom and Commonwealth. Director liability after board approval is a critical governance issue when boards authorise high-risk
EU Clinical Trial Data Acceptance: Is Cross-Border Recognition Mandatory?
EU clinical trial data acceptance tests the boundary between harmonised authorisation and regulatory autonomy. Does GCP compliance turn results from one Member State into
Microsoft Legal Agent Liability: Can “Legal Engineer” Positioning Weaken AI Disclaimers?
Microsoft Legal Agent Liability raises a significant question about whether contractual warnings can protect an AI provider when legal-workflow outputs cause foreseeable financial loss,
Korean Private Equity Restructuring after Closing
Korean private equity restructuring requires more than examining the acquisition agreement. The debate tests the tension between post-closing corporate control and the mandatory rules